Medical Professionals Online

Activity Of Vinflunine In Patients With Metastatic Renal Cell Carcinoma (RCC): A Phase II Study

May 26, 2017

UroToday - While metastatic RCC is thought to be largely a chemotherapy resistant disease, activity with some chemotherapeutic agents such as the vinca alkaloid vinblastine, with reported objective response rates in the range of 7-15%, has been noted. Vinflunine is a 3rd generation vinca alkaloid that has superior antitumor activity when compared to its parent compound vinblastine, in preclinical and phase I studies. In this report by Goldstein and colleagues, the activity of this compound as monotherapy, at two different dose levels administered every three weeks, in the treatment of metastatic RCC was investigated.

Thirty three patients with metastatic RCC and without prior therapy were included in this phase II study. One partial response was noted in the group that received 350mg/m2 and no responses were noted in the group that received 320 mg/m2, for a total response rate of 9.1%. The median progression free survival was 5.6 months for the group that received 350mg/m2 and 3.3 months for the group that received 320mg/m2. The overall survival for the entire group was 10.6 months.

The authors concluded that there was no clinically relevant activity of vinflunine as a monotherapy in the treatment of metastatic renal cell carcinoma.

By Christopher G. Wood, MD

Reference:
Goldstein D, et al., Invest New Drugs (Epub March 8, 2006)
Link Here.
Goldstein D, Ackland SP, Bell DR, Olver IN, Davis ID, Rosenthal MA, Toner GC, Pinel MC, Byrne M

UroToday - the only urology website with original content global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to:
urotoday

Copyright 2006 - UroToday